Immudex

With Immudex' proprietary Dextramer® and dCODE Dextramer® technologies, we develop and market reagents and assay solutions to measure disease-specific immunity.

[Immudex @immudex]

CAR-T cells come in different flavors 🍦 – here’s how to detect them!

We provide Custom CAR #Dextramer® reagents to match your target antigen.

💌Contact us at 𝐜𝐮𝐬𝐭𝐨𝐦𝐞𝐫@𝐢𝐦𝐦𝐮𝐝𝐞𝐱.𝐜𝐨𝐦

Learn more: https://t.co/qUT2XCfIdA

#CART #CellTherapy #Immunotherapy

[Immudex @immudex]

🔬DIY #Dextramer®! Create MHC Multimers in your own lab with the sensitivity and specificity that you expect from Dextramer® technology.

Learn more about U-Load Dextramer®: https://t.co/IUoo9Hev5L

#flowcytometry #Peptides #AntigenSpecificity #Immunology #immunemonitoring

[Immudex @immudex]

What are we celebrating at Immudex office today? Coming soon...

🌟 Stay tuned to find out more! 🌟

#Xynapse

[Immudex @immudex]

This means:
✅ Improved accuracy
✅ Better insights into CAR-T persistence
✅ More confidence in your data

Ready to see the difference?

Contact us at [email protected] to learn more!

#CART #CARTTherapy #CellTherapy #Immunotherapy #FlowCytometry

[Immudex @immudex]

More Sensitive Detection of CAR-T Cells!

Detect More, Detect Even Low CAR Expression.

When working with CAR-T cells, sensitivity is everything.

With CAR #Dextramer®, you can detect CAR-T cells with higher sensitivity, even when CAR expression is low.

+++

[Immudex @immudex]

Learn more about dCODE® reagents & Parean’s services: https://t.co/r8mMUdGbbx

#Partnership #ImmuneProfiling #SingleCell #Tcells #TCR #Bcells #BCR #Immunophenotyping

[Immudex @immudex]

🚀 Exciting Partnership Announcement! 🚀

We are thrilled to share that Immudex and Parean have joined forces to advance Immunophenotyping Services for the pharmaceutical industry! 🎉

By combining Immudex’s #dCODE® technology with Parean’s expertise in cytometry,

[Immudex @immudex]

✅ Deeper insights into immune responses
✅ Comprehensive TCR & BCR clonotype analysis
✅ Advanced single-cell multi-omics capabilities
✅ Outsource Immunophenotyping to a trusted service provider
✅ Enhanced innovation in cancer vaccines & immunotherapies

[Immudex @immudex]

DIY #Dextramer®! The U-Load #Dextramer® assembly protocol (MHC I) now includes illustrative graphics for a visual workflow overview. ✔️

We recommend including the quality control assay to determine the relative peptide loading efficiency.

Download now: https://t.co/4lONERQFs0

[Immudex @immudex]

to detect neoAg-specific CD8+ T cell responses, screening a total of 26 epitopes using this technology.

Check it out from Nature article: https://t.co/9MoGoVjfZ2

#DCtherapy #Neoantigen #immunotherapy #Celltherapy #Tcells #flowcytometry #Peptides #AntigenSpecificity #Immunology

[Immudex @immudex]

Boosting the activity of cross-presentating type 1 dendritic cells can broaden the neoAg-specific CD8+ T cell responses and leverage these #neoantigens for therapeutic advantage.

López et al. used U-Load #Dextramer® reagents in combination with H-2 Db easYmers®

[Immudex @immudex]

📥Download the FDA Guidance document from the link in the comments: Considerations for the Development of Chimeric Antigen Receptor (CAR) T Cell Products (Jan 2024)👇👇
https://t.co/oq1g45gUwC
#Dextramer #flowcytometry #CARTTherapy #CellTherapy #Immunotherapy #AntigenSpecificity

[Immudex @immudex]

When developing #CART therapies, analyzing viral-reactive #Tcells and understanding the T cell repertoire forms part of the guidance from the FDA (January 2024; page 22) It is important to ensure that the TCR repertoire is maintained in order to be able to fight viral infections

[Immudex @immudex]

Check out the poster abstract: https://t.co/5yPDjR9si1

#Dextramer #flowcytometry #CARTTherapy #CellTherapy #Immunotherapy #AntigenSpecificity

[Immudex @immudex]

🔬Analyzing viral-reactive #Tcells is important to ensure that #CART cells retain appropriate reactivity to viruses such as #CMV.

In a recent poster, Vittoria Biotherapeutics demonstrated how they not only analyze CMV-reactive T cells,

[Immudex @immudex]

but also study the T cell repertoire through TCR sequencing, to ensure little to no loss of viral-reactive TCRs during the 5-day manufacturing process of their CAR-T therapy targeting T cell lymphomas.

[Immudex @immudex]

💡 Benefit from greater flexibility for the detection of antigen-specific T and B cells by flow cytometry.

💡 Design panels including Dextramer®-based multimers and antibodies with ease.

Learn more: https://t.co/OzKuvorYL2

#Immunology #flowcytometry #immunemonitoring

[Immudex @immudex]

New Year, New Color? Our immune monitoring reagents are available with BV421! 💜

MHC #Dextramer®, U-Load® and Klickmer® reagents are available as standard products with the BV421 fluorochrome.

++

[Immudex @immudex]

🙌Read more about this milestone in our blog!
https://t.co/wr8xTa7pRQ

#CellTherapy #Tcelltherapy #immunotherapy #flowcytometry

[Immudex @immudex]

2024 has seen major milestones in TCR-T Cell Therapy - @immatics has published the First-in-Human dose escalation trial of an Anti-MAGEA1 TCR-T Cell Therapy in advanced solid tumours!

[Immudex @immudex]

MHC #Dextramer® reagents were used in the clinical trial of IMA202 from Immatics to quantify the MAGEA1-specific T cells for dose determination

see Wermke et al., JITC 2024: https://t.co/w9WVObkRQL